

on the induction of differentiation and lipogenesis, as in NB4 cells.

The basis for differentiation therapy of acute leukemia is the treatment of cells with several physiological agents at low concentration because high doses of single agents might provoke the side-effects of the agents and the resistance to the induction of differentiation. In this study, when PPAR $\gamma$  ligands were used alone, differentiation did not occur, but the combination of PPAR $\gamma$  ligand and ATRA synergistically promoted the differentiation of NB4 cells. The observed cooperativity between PPAR $\gamma$  ligands and ATRA has important implications for the use of combinations of these agents in differentiation therapy. PPAR $\gamma$ , like many members of the nuclear hormone receptor superfamily, functions as a heterodimer with the RXR. Recent studies have identified two types of RXR-dependent heterodimers: non-permissive and permissive (Schulman *et al.* 1998; Westin *et al.* 1998). In non-permissive heterodimers, such as those between RXR and RAR, the partner actively interferes with the ability of RXR-specific ligands. In contrast, permissive heterodimers, such as RXR-PPAR $\gamma$ , allow RXR signaling. In the current study, we demonstrated the synergistic effects of PPAR $\gamma$  ligands and ATRA on the differentiation of NB4 cells. The individual signaling pathways of RAR/RXR and PPAR $\gamma$ /RXR may have synergistically transduced signals for differentiation in NB4 cells. 9-*cis* RA, mono-*cis* isomers of retinoids, binds to RXR receptors in addition to RAR receptors and induces differentiation in HL-60 cells (Kizaki *et al.* 1993; Sakashita *et al.* 1993). However, 9-*cis* RA was clinically less effective for remission APL compared with ATRA. We did not perform experiments on the synergic effects of 9-*cis* RA with PPAR $\gamma$  ligands instead of ATRA in this study. Indeed, the duration of cell treatments being between 2 and 4 days, ATRA could be, at least partially, converted into 9-*cis* RA and 13-*cis* RA. In this case, the pathway of PPAR $\gamma$ /RXR may have induced differentiation by the synergic effects of 9-*cis* RA and PPAR $\gamma$  ligands. Further investigation will be needed to clarify this point.

In order to determine whether AD4833 or PGJ2 in fact binds PPAR $\gamma$  in NB4 cells, we examined the effects on differentiation using PPAR $\gamma$  or RXR antagonists. GW9662 and BADGE, both of which are specific PPAR $\gamma$  antagonists, significantly suppressed the differentiation of NB4 cells induced by PPAR $\gamma$  ligand and ATRA. The inhibitory effect of GW9662 was stronger than that of BADGE at the same concentration. Recently, Fehlberg *et al.* reported that high concentrations of BADGE induced apoptosis in tumor cells independently of PPAR $\gamma$  (Fehlberg *et al.* 2002).

In our study, NB4 cells did not show apoptosis because we used a low concentration of agonist (data not shown). HX531 is an RXR antagonist but acts also as a potential inhibitor of PPAR $\gamma$ /RXR in an *in vitro* transactivation assay and to prevent triglyceride accumulation in 3T3L1 adipocytes (Yamauchi *et al.* 2001). HX531 significantly inhibited the differentiation of NB4 cells induced by PPAR $\gamma$  ligand and ATRA. Both PPAR $\gamma$  and RXR antagonists suppressed this differentiation, indicating that AD4833 and PGJ2 act on the cells via PPAR $\gamma$ /RXR receptor.

With regard to the effects of PPAR $\gamma$  ligands on the accumulation of lipid in the cytoplasm, several studies using rosiglitazone have found that PPAR $\gamma$  may promote macrophage lipid accumulation (Nagy *et al.* 1998; Tontonoz *et al.* 1998; Chawla *et al.* 2001). Recently, the opposite theory was proposed, namely that PPAR $\gamma$  activation by rosiglitazone is not related to lipid accumulation in macrophages (Chinetti *et al.* 2001; Moore *et al.* 2001; Vosper *et al.* 2001). Our findings were consistent with the former theory, that is, lipid droplets accumulated during differentiation in NB4 cells treated with PPAR $\gamma$  ligand and ATRA. The triacylglycerol levels in PPAR $\gamma$  ligand- and ATRA-treated cells were obviously higher than that in cells treated with ATRA alone (Fig. 6b). These findings suggest that PPAR $\gamma$  accelerated the formation of lipid droplets by upregulating gene expression related to lipogenesis in NB4 cells. We examined the enzyme activity of glycerol-3-phosphate dehydrogenase (GPDH; EC 1.1.1.8), and the expression of CD36 (scavenger receptor-class B, fatty acid translocase). However, there was no difference in the enzyme activity or protein expression between PPAR $\gamma$  ligand and ATRA-treated and untreated cells. CD36 expression was not detected by fluorescence activated cell sorting analysis in either untreated or treated cells (data not shown). On the other hand, expression of aP2 mRNA in NB4 cells was upregulated by PPAR $\gamma$  ligand treatments (Fig. 4).

Furthermore, to elucidate the features of lipogenesis during differentiation, we examined the incorporation of fluorescent fatty acids in the cytoplasm. The fluorescent analogue was rapidly converted to triacylglycerols and targeted to the lipid droplets in NB4 cells treated with PPAR $\gamma$  ligand and ATRA. Large lipid droplets from adipocytes, rich in triacylglycerols, are retained within the cells as a source of fatty acids for mitochondrial and peroxisomal oxidation to produce energy (Brasaemle *et al.* 1997). However, almost all other mammalian tissues examined contain small lipid droplets, which are less well characterized (Atshaves *et al.* 1998; Murphy & Vance 1999; Sparrow *et al.* 1999). Burns *et al.* reported that human neutrophils

take up much more fatty acid than lymphocytes primarily because they synthesize much larger quantities of triacylglycerols, a fatty acid storage form (Burns *et al.* 1976). It is postulated that lipid droplets may represent the storage form for free fatty acids which may be utilized for membrane synthesis during phagocytosis (Elsbach 1964; Elsbach & Farrow 1969; Lutas & Zucker-Franklin 1977). In these theories, the differentiation of phagocytes is accompanied by lipid droplet accumulation. We also examined the biosynthesis of triacylglycerols using fluorescent fatty acid. The results demonstrated that the rate of triacylglycerol synthesis is more than twofold greater in differentiated cells. From the results of triacylglycerol enzyme activity assays, we suggest that triacylglycerols are synthesized from glycerol but not dihydroxyacetone phosphate in PPAR $\gamma$  ligand- and ATRA-treated cells. In adipocytes, thiazolidinediones markedly induce glycerol kinase gene expression and stimulate the incorporation of glycerol rather than glucose into triacylglycerol (Guan *et al.* 2002). In the synthesis of glycerolipids, it is well established that glycerol has to be phosphorylated to glycerol-3-phosphate before acylation occurs. However, in the microsomal fraction of heart, liver, kidney, skeletal muscle and brain tissues, direct acylation of glycerol becomes more prominent when exogenous glycerol levels become elevated (Lee *et al.* 2001). Both of those reports are in accord with our conclusion that glycerol was used as substrate in triacylglycerol synthesis. Further investigations will be required to determine the relationship between differentiation and the accumulation of lipid droplets in acute myeloid leukemia treated with PPAR $\gamma$  ligands and ATRA.

### Acknowledgement

We thank the Takeda Pharmaceutical Company (Tokyo, Japan) for providing AD4833.

### References

- Asou, H., Verbeek, W., Williamson, E. *et al.* 1999. Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor  $\gamma$ , and retinoids. *Int. J. Oncol.* **15**, 1027–1031.
- Atshaves, B. P., Foxworth, W. B., Frolov, A. *et al.* 1998. Cellular differentiation and I-FABP protein expression modulate fatty acid uptake and diffusion. *Am. J. Physiol.* **274**, C633–C644.
- Boehm, M. F., Zhang, L., Zhi, L. *et al.* 1995. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. *J. Med. Chem.* **38**, 3146–3155.
- Brasaemle, D. L., Barber, T., Wolins, N. E., Serrero, G., Blanchette-Mackie, E. J. & Londos, C. 1997. Adipose differentiation-related protein is an ubiquitously expressed lipid storage droplet-associated protein. *J. Lipid Res.* **38**, 2249–2263.
- Breitman, T. R., Selonick, S. E. & Collins, S. J. 1980. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. *Proc. Natl Acad. Sci. USA* **77**, 2936–2940.
- Burns, C. P., Welshman, I. R. & Spector, A. A. 1976. Differences in free fatty acid and glucose metabolism of human blood neutrophils and lymphocytes. *Blood* **47**, 431–437.
- Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P. & Evans, R. M. 2001. PPAR- $\gamma$  dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. *Nat. Med.* **7**, 48–52.
- Chawla, A., Schwarz, E. J., Dimaculangan, D. D. & Lazar, M. A. 1994. Peroxisome proliferator-activated receptor (PPAR)  $\gamma$ : adipose-predominant expression and induction early in adipocyte differentiation. *Endocrinology* **135**, 798–800.
- Chinetti, G., Lestavel, S., Bocher, V. *et al.* 2001. PPAR- $\alpha$  and PPAR- $\gamma$  activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. *Nat. Med.* **7**, 53–58.
- Cornic, M., Delva, L., Guidez, F., Balitrand, N., Degos, L. & Chomienne, C. 1992. Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. *Cancer Res.* **52**, 3329–3334.
- Degos, L. 1992. Retinoic acid in acute promyelocytic leukemia: a model for differentiation therapy. *Curr. Opin. Oncol.* **4**, 45–52.
- Ebisawa, M., Umemiya, H., Ohta, K. *et al.* 1999. Retinoid X receptor-antagonistic diazepinylbenzoic acids. *Chem. Pharm. Bull. (Tokyo)* **47**, 1778–1786.
- Elsbach, P. 1964. Comparison of Uptake of Palmitic, Stearic, Oleic and Linoleic Acid by Polymorphonuclear Leukocytes. *Biochim. Biophys. Acta* **84**, 8–17.
- Elsbach, P. & Farrow, S. 1969. Cellular triglyceride as a source of fatty acid for lecithin synthesis during phagocytosis. *Biochim. Biophys. Acta* **176**, 438–441.
- Fehlberg, S., Trautwein, S., Goke, A. & Goke, R. 2002. Bisphenol A diglycidyl ether induces apoptosis in tumour cells independently of peroxisome proliferator-activated receptor- $\gamma$ , in caspase-dependent and -independent manners. *Biochem. J.* **362**, 573–578.
- Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M. & Evans, R. M. 1995. 15-Deoxy- $\Delta$  12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR  $\gamma$ . *Cell* **83**, 803–812.
- Gearing, K. L., Gottlicher, M., Teboul, M., Widmark, E. & Gustafsson, J. A. 1993. Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. *Proc. Natl Acad. Sci. USA* **90**, 1440–1444.
- Greenspan, P., Mayer, E. P. & Fowler, S. D. 1985. Nile red: a selective fluorescent stain for intracellular lipid droplets. *J. Cell Biol.* **100**, 965–973.
- Guan, H. P., Li, Y., Jensen, M. V., Newgard, C. B., Stepan, C. M. & Lazar, M. A. 2002. A futile metabolic cycle activated in adipocytes by antidiabetic agents. *Nat. Med.* **8**, 1122–1128.
- Hirase, N., Yanase, T., Mu, Y. *et al.* 1999. Thiazolidinedione induces apoptosis and monocytic differentiation in the promyelocytic leukemia cell line HL60. *Oncology* **57** (Suppl. 2), 17–26.
- Hu, Z. B., Ma, W., Uphoff, C. C., Lanotte, M. & Drexler, H. G. 1993. Modulation of gene expression in the acute promyelocytic leukemia cell line NB4. *Leukemia* **7**, 1817–1823.

- Huang, M. E. Ye, Y. C., Chen, S. R. *et al.* 1988. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. *Blood* **72**, 567–572.
- Kizaki, M., Ikeda, Y., Tanosaki, R. *et al.* 1993. Effects of novel retinoic acid compound, 9-cis-retinoic acid, on proliferation, differentiation, and expression of retinoic acid receptor- $\alpha$  and retinoid X receptor- $\alpha$  RNA by HL-60 cells. *Blood* **82**, 3592–3599.
- Kliwer, S. A., Umesono, K., Mangelsdorf, D. J. & Evans, R. M. 1992a. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. *Nature* **355**, 446–449.
- Kliwer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A. & Evans, R. M. 1992b. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. *Nature* **358**, 771–774.
- Lee, D. P., Deonaraine, A. S., Kienetz, M. *et al.* 2001. A novel pathway for lipid biosynthesis: the direct acylation of glycerol. *J. Lipid Res.* **42**, 1979–1986.
- Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M. & Kliwer, S. A. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor  $\gamma$  (PPAR  $\gamma$ ). *J. Biol. Chem.* **270**, 12 953–12 956.
- Lutas, E. M. & Zucker-Franklin, D. 1977. Formation of lipid inclusions in normal human leukocytes. *Blood* **49**, 309–320.
- Moore, K. J., Rosen, E. D., Fitzgerald, M. L. *et al.* 2001. The role of PPAR- $\gamma$  in macrophage differentiation and cholesterol uptake. *Nat. Med.* **7**, 41–47.
- Mueller, E., Sarraf, P., Tontonoz, P. *et al.* 1998. Terminal differentiation of human breast cancer through PPAR  $\gamma$ . *Mol. Cell* **1**, 465–470.
- Murphy, D. J. & Vance, J. 1999. Mechanisms of lipid-body formation. *Trends Biochem. Sci.* **24**, 109–115.
- Nagy, L., Tontonoz, P., Alvarez, J. G., Chen, H. & Evans, R. M. 1998. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR  $\gamma$ . *Cell* **93**, 229–240.
- Ohta, K., Kawachi, E., Inoue, N. *et al.* 2000. Retinoidal pyrimidinecarboxylic acids. Unexpected diaza-substituent effects in retinobenzoic acids. *Chem. Pharm. Bull. (Tokyo)* **48**, 1504–1513.
- Rosen, E. D., Sarraf, P., Troy, A. E. *et al.* 1999. PPAR  $\gamma$  is required for the differentiation of adipose tissue in vivo and in vitro. *Mol. Cell* **4**, 611–617.
- Sakashita, A., Kizaki, M., Pakkala, S. *et al.* 1993. 9-cis-retinoic acid: effects on normal and leukemic hematopoiesis in vitro. *Blood* **81**, 1009–1016.
- Schulman, I. G., Shao, G. & Heyman, R. A. 1998. Transactivation by retinoid X receptor-peroxisome proliferator-activated receptor  $\gamma$  (PPAR  $\gamma$ ) heterodimers: intermolecular synergy requires only the PPAR  $\gamma$  hormone-receptor activation function. *Mol. Cell Biol.* **18**, 3483–3494.
- Sparrow, C. P., Patel, S., Baffic, J. *et al.* 1999. A fluorescent cholesterol analog traces cholesterol absorption in hamsters and is esterified in vivo and in vitro. *J. Lipid. Res.* **40**, 1747–1757.
- Thuillier, P., Baillie, R., Sha, X. & Clarke, S. D. 1998. Cytosolic and nuclear distribution of PPAR  $\gamma$  2 in differentiating 3T3-L1 preadipocytes. *J. Lipid Res.* **39**, 2329–2338.
- Tontonoz, P., Hu, E. & Spiegelman, B. M. 1994. Stimulation of adipogenesis in fibroblasts by PPAR  $\gamma$  2, a lipid-activated transcription factor. *Cell* **79**, 1147–1156.
- Tontonoz, P., Nagy, L., Alvarez, J. G., Thomazy, V. A. & Evans, R. M. 1998. PPAR  $\gamma$  promotes monocyte/macrophage differentiation and uptake of oxidized LDL. *Cell* **93**, 241–252.
- Vosper, H., Patel, L., Graham, T. L. *et al.* 2001. The peroxisome proliferator-activated receptor  $\delta$  promotes lipid accumulation in human macrophages. *J. Biol. Chem.* **276**, 44 258–44 265.
- Westin, S., Kurokawa, R., Nolte, R. T. *et al.* 1998. Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. *Nature* **395**, 199–202.
- Willson, T. M., Lambert, M. H. & Kliwer, S. A. 2001. Peroxisome proliferator-activated receptor  $\gamma$  and metabolic disease. *Annu. Rev. Biochem.* **70**, 341–367.
- Wright, H. M., Clish, C. B., Mikami, T. *et al.* 2000. A synthetic antagonist for the peroxisome proliferator-activated receptor  $\gamma$  inhibits adipocyte differentiation. *J. Biol. Chem.* **275**, 1873–1877.
- Yamauchi, T., Waki, H., Kamon, J. *et al.* 2001. Inhibition of RXR and PPAR  $\gamma$  ameliorates diet-induced obesity and type 2 diabetes. *J. Clin. Invest* **108**, 1001–1013.
- Yasugi, E., Uemura, I., Kumagai, T., Nishikawa, Y., Yasugi, S. & Yuo, A. 2002. Disruption of mitochondria is an early event during dolichyl monophosphate-induced apoptosis in U937 cells. *Zool. Sci.* **19**, 7–13.
- Zilberfarb, V., Siquier, K., Strosberg, A. D. & Issad, T. 2001. Effect of dexamethasone on adipocyte differentiation markers and tumour necrosis factor- $\alpha$  expression in human PAZ6 cells. *Diabetologia* **44**, 377–386.



## Neutrophil activation and induced by *C. albicans* water-soluble mannoprotein- $\beta$ -glucan complex (CAWS)

Akiko Ishida-Okawara <sup>a</sup>, Noriko Nagi-Miura <sup>a,b</sup>, Toshiaki Oharaseki <sup>a,c</sup>, Kei Takahashi <sup>c</sup>, Akinori Okumra <sup>a</sup>, Hitoshi Tachikawa <sup>a,d</sup>, Shin-ichiro Kashiwamura <sup>e</sup>, Haruki Okamura <sup>e</sup>, Naohito Ohno <sup>b</sup>, Hidechika Okada <sup>f</sup>, Peter A. Ward <sup>g</sup>, Kazuo Suzuki <sup>a,\*</sup>

<sup>a</sup> Department of Bioactive Molecules, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku-ku, Tokyo, 162-8640, Japan

<sup>b</sup> Laboratory of Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Science, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan

<sup>c</sup> Department of Pathology, Ohashi Hospital, Toho University School of Medicine, 2-17-6, Ohashi, Meguro-ku, Tokyo, 153-8515, Japan

<sup>d</sup> Department of Clinical Pharmacology, Niigata University of Pharmacy and Applied Life Sciences, Asahimachi-dori 1, Niigata, Niigata 951-8510, Japan

<sup>e</sup> Department of Physiology, Hyogo College of Medicine, 1-1, Mukokawa-cho, Nishinomiya-city, Hyogo, 663-8131, Japan

<sup>f</sup> Nagoya City University, Graduate School of Medicine, 1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya-city, Aichi, 467-8601, Japan

<sup>g</sup> Department of Pathology, The University of Michigan Medical School, Ann Arbor, MI 48109, USA

Received 4 May 2006

### Abstract

We have established a mouse model which shows the symptoms of coronary arteritis after consecutive injections of CAWS, which is released from *Candida albicans*. In this study, we examined neutrophil activation in the initial period after CAWS injection intraperitoneally. During 10 min to 16 h after the injection, blood profiles and neutrophil functions were determined. At the same time, levels of inflammatory cytokines and chemokines in plasma were measured. Furthermore, level of ICAM-1 as a marker of lesion endothelial cell. Counts of the peripheral leukocytes increased immediately after CAWS injection, especially neutrophil. In vitro sensitivity of neutrophils to stimuli was enhanced. Moreover, proinflammatory cytokines (IL-1 $\beta$ , IL-12 and IL-6), in plasma initially followed by an increase in IL-10, G-CSF, MIP-2 and soluble ICAM-1. Locally, ICAM-1 message in arterial walls was significantly increased 16 h after CAWS injection. A decrease in C3 levels was observed in plasma, suggesting complement activation and consumption. In summary, neutrophil activation occurred after CAWS injection, followed by complement activation, and production of proinflammatory cytokines chemokines and G-CSF which may be involved in development of coronary arteritis.

© 2006 Published by Elsevier Inc.

**Keywords:** Complement activation; Inflammatory cytokines; Endothelium injury

### Introduction

Recently, clinical relevance of fungal diseases has increased, mainly because of an increasing population of immunocompromised individuals including those infected with HIV,

transplant recipients and patients with cancer (Zupanic-Krmek and Nemet, 2004). Neutrophils play a key role during *Candida albicans* infection (Urban et al., 2006; Fradin et al., 2005). *C. albicans* exposed to erythrocytes, mononuclear cells, plasma or blood lacking neutrophils physiologically active and rapidly switch to filamentous growth. In contrast, the presence of neutrophils arrested *C. albicans* growth (Urban et al., 2006; Fradin et al., 2005). Recently, immune responses to some components of *C. albicans* such as mannan (Muller and Melchinger, 2004) or  $\beta$ -glucan (Gantner et al., 2005) have been reported.

**Abbreviations:** CAWS, *C. albicans* water-soluble mannoprotein- $\beta$ -glucan complex; fMLP, fMet-Leu-Phe.

\* Corresponding author. Fax: +81 3 5285 1160.

E-mail address: ksuzuki@nih.go.jp (K. Suzuki).

46 Animal model is useful to clarify mechanism of infection  
47 process, genetic background differences and to strategy for  
48 therapy (Nagi-Miura et al., 2004; Aratani et al., 2002; Spellberg  
49 et al., 2005).

50 Some microorganisms or microorganism-derived products  
51 are specific diseases. For example, certain *Campylobacter*  
52 *jejuni* strains trigger Guillain–Barre syndrome while other  
53 strains trigger the Fisher syndrome in the Japanese population  
54 (Takahashi et al., 2005). Esper et al. have reported that New  
55 Haven coronavirus (HCoV-NH) infection is associated with  
56 Kawasaki disease (Esper et al., 2005). Recently, Iwai et al. have  
57 identified oral microorganisms in the lesions of Buerger disease,  
58 suggesting a possible etiologic link between Buerger disease  
59 and chronic infections such as oral bacterial infections (Iwai et  
60 al., 2005). We have established a mouse model which shows the  
61 symptoms of coronary arteritis following consecutive injections  
62 into mice of a water-soluble polysaccharide (CAWS) (Nagi-  
63 Miura et al., 2004; Ohno, 2003). In this study, we examined  
64 neutrophil activation and subsequent events after a single  
65 injection of CAWS (Fig. 1).

## 66 Materials and methods

### 67 Reagents

68 ELISA kits for mouse IL-1 $\beta$ , IL-6, IL-10, IL-12 p70, IFN- $\gamma$ , TNF- $\alpha$  were  
69 purchased from BD Biosciences (CA, USA), IL-18 was from Medical and

Biological Laboratories (Tokyo, Japan), soluble ICAM-1 and MIP-2 were from  
70 R&D Systems (MN, USA), G-CSF and GM-CSF were from AN'ALYZA (MN,  
71 US). fMet-Leu-Phe (fMLP) was purchased from Peptide Institute (Osaka,  
72 Japan), 3,3',5,5'-tetramethylbenzidine (TMB), cytochalasin B (CB), cytochrome  
73 c, RPMI 1640 medium, aprotinin and PMSF were purchased from Sigma  
74 Chemical Co. (MO, USA). Casein was purchased from Calbiochem. Co.  
75 (Darmstadt, Germany). TaqMan Universal PCR master mix was purchased from  
76 PE Biosystems (NJ, USA). Monoclonal antibody and peroxidase-conjugated  
77 IgG fraction to mouse C3 were purchased from HyCult biotechnology (Uden,  
78 The Netherlands) and MP Biochemicals, Inc. (CA, USA), respectively.  
79

### Mice

80  
81 C57BL/6N male mice were purchased from Charles River Japan, kept under  
82 SPF conditions, and used according to a guideline for animal care of the  
83 National Institute of Infectious Diseases. The mice were used in the experiment  
84 at 6 weeks of age.

### Preparation and administration of CAWS

85  
86 CAWS was prepared from *C. albicans* strain IFO1385 in accordance with  
87 conventional methods (Nagi-Miura et al., 2004). CAWS was dissolved in PBS  
88 autoclaving, 0.2 ml of the (20 mg/ml) was intraperitoneally injected into a  
89 mouse. For vitro assay, neutrophils isolated from 8% casein-induced peritoneal  
90 exudated cells were co-cultured with CAWS in RPMI medium containing  
91 0.3 mM PMSF and 0.4  $\mu$ g/ml aprotinin.

### Histological observations of coronary arteritis

92  
93 Coronary artery segments were fixed in 10% buffered (pH7.2) formalde-  
94 hyde, paraffin-embedded, and sections stained with hematoxylin and eosin.




Fig. 1. Histological analysis of coronary arteritis administration of a single dose of CAWS. Normal (a) aortic root including coronary artery  $\times 40$ , (b) coronary artery  $\times 200$  and (c) aorta,  $\times 200$ . Histology 4 weeks after CAWS injection a single dose of 4 mg/mouse vasculitis at the coronary artery and aortic root,  $\times 40$ , (e) coronary arteritis,  $\times 200$ , (f) aortitis,  $\times 200$ .

95 *Analysis of leukocytes profile*

96 Peripheral blood was collected from heart and EDTA-2K was added.  
97 Leukocyte profiles were analyzed by use of automation instruments (Mitsubishi  
98 BCL Corp., Tokyo, Japan).

99 *Flow cytometric analysis*

100 Peripheral blood was collected from heart and EDTA-2K was added.  
101 After lysis for 5 min at 4 °C, subsequent centrifugation (1000×g at 4 °C,  
102 cells) was suspended in HBSS. Bone marrow cells were prepared from a  
103 shinbone. The cells were incubated with mAb against surface markers (BD  
104 Pharmingen, CA, USA). Gr-1 (RB6-8C5), Mac-1 (M1/70) were used for flow  
105 cytometric analysis, and then analyzed with FACSCalibur using CellQuest  
106 software (BD Biosciences, CA, USA).

107 *Neutrophil function assay*

108 Heparinized blood was collected from heart, and neutrophil was prepared.  
109 MPO release and superoxide generation were measured as described previously  
110 (Ishida-Okawara et al., 1991).

111 *Measurement of proinflammatory cytokines and chemokine in  
112 plasma*

113 Levels of proinflammatory cytokines IL-1 $\beta$ , IL-6, IL-10, IL-12, IL-18,  
114 TNF- $\alpha$ , INF- $\gamma$ , MIP-2, soluble ICAM-1, G-CSF, GM-CSF in plasma using  
115 individual ELISA.

116 *Preparation of peritoneal exudate neutrophils and measurement of  
117 cytokine production level by co-cultured neutrophil with CAWS*

118 Normal C57BL/6N mice were intraperitoneally injected with 4 ml of 8%  
119 casein in PBS and exudate cells containing resident macrophage or casein-  
120 induced neutrophils were recovered 8 h lavage with 5 ml of PBS. The  
121 exudate cells were put onto M-SMF (Japan Immunoresearch Laboratories

Co., Ltd., Takasaki, Japan), centrifuged 1200×g for 20 min at room 122  
temperature. Neutrophils were suspended ( $5 \times 10^6$  cells/ml) in RPMI-1640 123  
medium containing 0.3 mM PMSF and 0.4  $\mu$ g/ml aprotinin and co-cultured 124  
with 1 mg/ml CAWS for 0.5 to 4 h. At the end of culture, culture supernatant 125  
was prepared by centrifugation and levels of cytokines IL-1 $\beta$ , IL-6, IL-10 126  
determined using by ELISA kits. 127

128 *Measurement of ICAM-1 mRNA expressed in aortic wall after CAWS  
129 injection*

130 The thoracic aortas of mice were was isolated and frozen immediately for 130  
detection of ICAM-1 mRNA. The total aortic RNA for each mouse was 131  
isolated using ISOGEN (Nippon ene, Tokyo Japan). One microgram of RNA 132  
was reverse transcribed with ReverTra Ace (Toyobo, Osaka, Japan) to obtain 133  
cDNA. Real-time PCR was performed using ABI PRISM 7000 Sequence 134  
Detection System (Applied Biosystems, CA, US) according to the manufac- 135  
ture's protocol. Primers and TaqMan probes specific for ICAM-1 was 136  
obtained from Assay-on-Demand Gene Expression Products (Applied 137  
Biosystems). For endogenous control, the level of GAPDH in each sample 138  
was measured using TaqMan Rodent GAPDH Control Reagents VIC 139  
(Applied Biosystems). Data analyses were performed on ABI PRISM 7000 140  
SDS software version 1.0 (Applied Biosystems). 141

142 *Detection of mouse complement 3 (C3) by ELISA and Western  
143 blotting*

144 Peripheral blood was collected from heart and EDTA-2K was added. 144  
One  $\mu$ g/ml of C3 monoclonal antibody was coated to ELISA plate for 145  
overnight. After washing, blocking was done by 50% FCS for 1 h. 146  
Sample plasma ( $\times 100$ ) was added to the plate for 1 h, after washing 147  
peroxidase labeled-2nd antibody ( $\times 1000$ ) was added to the plate. After 148  
washing, *o*-phenylenediamine chloride was added to the plate for 3 min. 149  
Finally, reaction was stopped 2 N hydrogen sulphate and measured at 150  
490 nm by auto reader (Nippon Bunko, Tokyo, Japan). Western blotting was 151  
performed by using mouse C3 monoclonal antibody and peroxidase-labeled 152  
anti-Rat IgG as 2nd antibody. 153




Fig. 2. Change of blood profile after CAWS injection. Peripheral blood was collected from heart EDTA-2K. Blood profile was analyzed by Mitsubishi Kagaku BCL Inc. (a) total leukocyte number, ratio of (b) neutrophil, (c) lymphocyte and (d) monocyte, respectively.  $N=6$  in each group.

t1.1 Table 1  
t1.2 Change of Gr-1<sup>+</sup> cells ratio after CAWS injection

		Time after CAWS injection (hr)					
		0	0.17	0.5	1	4	16
t1.5	Bone marrow	19.47±5.35	15.85±1.89	9.65±1.14 *	10.42±1.26 *	7.39±1.97 *	11.73±6.58
t1.6	Peripheral blood	5.24±6.92	5.30±0.36	10.35±2.00 *	9.78±3.59	8.06±6.69	6.12±5.34

t1.7 \* P<0.05.

154 *Statistical analysis*

155 Results expressed as the mean±SD. Statistical analysis was using Mann-  
156 Whitney U-test. The probability value of <0.05 considered significant.

157 **Results**

158 *Observation of coronary arteritis administration of a single*  
159 *dose of CAWS*

160 We have severe coronary arteritis by daily injection of  
161 CAWS (4 mg/mouse/day) for 5 days. In order to compare  
162 initial events and development of coronary arteritis, the  
163 current studies employed a one shot injection of CAWS at a  
164 dose of 4 mg/mouse. Four weeks after CAWS injection with  
165 this protocol, arteritis was evident in both coronary and aorta.

166 *Profiles of peripheral leukocytes*

167 After CAWS injection, total leukocyte counts were increased  
168 and later returned to baseline levels 4 h (Fig. 2a). The ratio of

lymphocytes decreased after CAWS injection, while ratio of  
neutrophils promptly increased (Figs. 2b, c), the ratio of  
monocyte increased (Fig. 2d).

*Profile of leukocyte by flow cytometric analysis*

To confirm the leukocyte counts, flow cytometric  
analysis of peripheral and bone marrow cells after  
CAWS injection was done (Table 1). Bone marrow cell  
numbers the tibia were significantly increased 4 h after  
CAWS injection (data not shown). The ratio of Gr-1 cells  
in bone marrow significantly decreased at 0.5, 1, 4 h after  
CAWS injection, while the ratio of the cells in peripheral  
blood increased suggesting that neutrophils in bone  
marrow promptly migrate to peripheral blood CAWS  
injection.

*CAWS effect on neutrophil activation*

To the functional response of neutrophils after CAWS  
injection, MPO release and superoxide generation were




Fig. 3. Neutrophil activation after CAWS injection. (a, b) MPO release from neutrophils after CAWS injection. Neutrophils (10<sup>6</sup> cells/ml) were stimulated in the (a) absence, or (b) presence of (10<sup>-5</sup> M) and (5 μg/ml). (c, d) Superoxide generation after CAWS injection. Neutrophils (10<sup>6</sup> cells/ml) were stimulated with (c) (10<sup>-5</sup> M) and (5 μg/ml) or (d) PMA (1 μg/ml). N=6 in each group.



186 examined (Fig. 3). fMLP-induced MPO release from neu-  
187 trophils was enhanced after CAWS injection (Fig. 3b), while  
188 spontaneous MPO release was not changed (Fig. 3a). In  
189 addition, both fMLP and PMA-induced superoxide genera-  
190 tion was enhanced following in vivo CAWS injection (Figs.  
191 3c, d).

#### 192 CAWS effects on proinflammatory cytokine production

193 Since activation of neutrophils was observed, after in  
194 vivo injection of CAWS, proinflammatory cytokines levels  
195 in plasma were measured (Fig. 4). IL-12 p70 production  
196 was increased IL-1 $\beta$  (b), IL-10 (c), IL-6 (d) significantly  
197 increased CAWS injection. Levels of MIP-2 and G-CSF in  
198 plasma increased after CAWS injection and 16 h after  
199 CAWS injection (Figs. 4e, f). On the other hand, IL-18,  
200 TNF- $\alpha$ , INF- $\gamma$ , GM-CSF were not detected up to 16 h  
201 after CAWS injection (data not shown). Since IL-1 $\beta$ , IL-  
202 10, IL-6 was significantly increased, production of these  
203 cytokines by casein-induced neutrophils was also measured  
204 (Fig. 5). IL-6 production was enhanced by exposure of  
205 neutrophils to CAWS (Fig. 5c), while IL-11L-10 was  
206 nearly the same in presence or absence of CAWS (Figs.  
207 5a, b).

#### CAWS effect of ICAM-1 expression and soluble ICAM release 208

209 Since ICAM-1 is a marker of activation of endothelial cells,  
210 we ICAM-1 gradually increased in plasma after CAWS  
211 injection (Fig. 6a). In addition, ICAM-1 the thoracic aortic  
212 wall was also significantly increased 16 h after CAWS injection  
213 (Fig. 6b).

#### CAWS C3 activation 214

215 Activation of C3 was examined (Fig. 7). C3 decreased  
216 time dependently after CAWS injection and gradually  
217 (Fig. 7a). This was confirmed by Western blotting  
218 analysis (Fig. 7b). These results suggest that neutrophil  
219 activation triggered through complement activation by a  
220 single injection.

#### Discussion 221

222 In study, we focused on neutrophil activation related to  
223 development of coronary arteritis. Single injection of  
224 CAWS at a dose of 4 mg/mouse induced coronary  
225 arteritis 4 weeks featuring neutrophil accumulation in the  
226 coronary arterial wall. This observation was similar to the 226




Fig. 4. Cytokine after CAWS injection. Heparinized blood was obtained from heart after CAWS injection. Plasma was separated and proinflammatory cytokines level was measured by ELISA kit. IL-12 p70, (b) IL-1 $\beta$ , (c) IL-10, (d) IL-6, (e) MIP-1, (f) G-CSF, respectively.  $N=6$  in each group.






Fig. 5. Cytokine production by neutrophil. Casein-induced neutrophil ( $5 \times 10^6$  cells/ml) suspended in RPMI-1640 containing 0.3 mM PMSF and 1.4  $\mu$ g/ml aprotinin and co-cultured with 1 mg/ml CAWS for 0.5 to 4 h. Culture supernatant was prepared by centrifugation and level of cytokine. (a) IL-1 $\beta$ , (b) IL-10 and (c) IL-6, respectively.  $\circ$  not treated by CAWS  $\bullet$  1 mg/ml of CAWS.  $N=3-6$  in each group.

227 development of coronary arteritis daily injection of CAWS  
228 (4 mg/mouse/day) 5 days (Nagi-Miura et al., 2004; Ohno,  
229 2003).

Blood neutrophils and subsequently monocyte increased, 230  
while lymphocyte counts decreased. In addition, the ratio of Gr- 231  
1 cells in bone marrow decreased, suggesting migration of 232  
neutrophils from bone marrow into peripheral blood after 233  
CAWS injection. G-CSF after CAWS injection, fMLP-induced 234  
MPO release from neutrophils was enhanced as was PMA and 235  
fMLP-induced superoxide generation in vivo injection. These 236  
results suggest that number of blood neutrophils their activation 237  
early after CAWS injection. 238

Levels of IL-1 $\beta$ , IL-6, and IL-10 significantly increased 239  
in plasma after CAWS injection. These cytokines are also 240  
blood leukocytes live *C. albicans* (Netea et al., 2002; 241  
Gasparoto et al., 2004). The of cytokines seems to be 242  
different depend on *Candida* strain, component and 243  
virulence (Villar et al., 2005). With regard to casein- 244  
induced neutrophils, IL-6 was significantly enhanced by co- 245  
culture with CAWS, but IL-1 $\beta$  and IL-10 production 246  
virtually unchanged in presence of CAWS. These results 247  
suggest IL-6 production especially enhanced by CAWS. 248  
MIP-2 and G-CSF in plasma were maintained for 16 h, 249  
neutrophil levels in blood MIP-2 and G-CSF in blood. 250

Because of increase and activation of peripheral neutrophils, 251  
complement activation products may well be candidate because 252  
C5a is a chemoattractant for neutrophils (Guo and Ward, 2005). 253  
Ohno et al. have already demonstrated activation of the lectin 254  
complement pathway by CAWS (unpublished). Mullick A. et 255  
al. have confirmed dysregulated cytokine response during *C.* 256  
*albicans* infection (Mullick et al., 2004). 257

Soluble ICAM-1, which is a marker of activated endothelial 258  
cells (Iiyama et al., 1999), in blood increased after CAWS 259  
injection. In addition, ICAM-1 message was significantly 260  
increased in the thoracic aortic wall 16 h after CAWS injection. 261  
Both systemic and local increases in ICAM-1 could be involved 262  
to subsequent endothelial cell lesion development (Di Lorenzo 263  
et al., 2004). 264

In summary, increased numbers and activation of peripheral 265  
blood neutrophils are the initial events after CAWS injection, 266  
perhaps followed by macrophage activation and adaptive 267  
immune responses. Neutrophil a primary role in biodefense 268




Fig. 6. Soluble ICAM-1 in plasma and ICAM-1 mRNA in aorta after CAWS injection. (a) Heparinized blood was obtained from heart after CAWS injection. Plasma was separated and ICAM-1 level was measured by ELISA kit. (b) Total RNA was extracted and mRNA isolated. cDNA was prepared from 1  $\mu$ g of mRNA. Real-time PCR was performed and analyzed. GAPDH was used as an internal control. White bar shows not treated by CAWS, black bar shows treated by 4 mg/mouse of CAWS, respectively.  $N=6$  in each group.




Fig. 7. Mouse complement 3 (C3) was assessed in plasma by sandwich ELISA and Western blotting. 10 mM EDTA treated blood was prepared from heart after CAWS injection. (a) C3 protein was detected by sandwich ELISA using monoclonal and peroxidase-labeled polyclonal antibody, (b)  $\alpha$  chain of C3 was detected by monoclonal antibody to mouse C3.

269 against *C. albicans* or its products. Arteritis induced by CAWS  
270 might be.

#### 271 Uncited reference

272 Collins et al., 2000

#### 273 Acknowledgments

274 This work was supported in part by grants for vascular  
275 diseases from Ministry of Health Labor and Welfare of Japan  
276 and Japan Health Science Foundation.

#### 277 References

- 278 Aratani, Y., Kura, F., Watanabe, H., Takano, Y., Suzuki, K., Dinuer, M.C.,  
279 Maeda, N., Koyama, H., 2002. Relative contributions of myeloperoxidase  
280 and NADPH-oxidase to the early host defense against pulmonary infections  
281 with *Candida albicans* and *Aspergillus fumigatus*. *Med. Mycol.* 40,  
282 557–563.
- 283 Collins, R.G., Velji, R., Guevara, N.V., Hicks, M.J., Chan, L., Beaudet, A.L.,  
284 2000. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency  
285 substantially protects against atherosclerosis in apolipoprotein E-deficient  
286 mice. *J. Exp. Med.* 191, 189–194.
- 287 Di Lorenzo, G., Pacor, M.L., Mansueto, P., Lo Bianco, C., Di Natale, E.,  
288 Rapisarda, F., Pellitteri, M.E., Ditta, V., Gioe, A., Giammarresi, G., Rini,  
289 G.B., Li Vecchi, M., 2004. Circulating levels of soluble adhesion  
290 molecules in patients with ANCA-associated vasculitis. *J. Nephrol.* 17,  
291 800–807.
- 292 Esper, F., Shapiro, E.D., Weibel, C., Ferguson, D., Landry, M.L., Kahn, J.S.,  
293 2005. Association between a novel human coronavirus and Kawasaki  
294 disease. *J. Infect. Dis.* 191, 499–502.
- 295 Fradin, C., De Groot, P., Mac Callum, D., Schaller, M., Klis, F., Odds, F.C.,  
296 Hube, B., 2005. Granulocytes govern the transcriptional response,  
297 morphology and proliferation of *Candida albicans* in human blood. *Mol.*  
298 *Microbiol.* 56, 397–415.
- 299 Gantner, B.N., Simmons, R.M., Underhill, D.M., 2005. Dectin-1 mediates  
300 macrophage recognition of *Candida albicans* yeast but not filaments.  
301 *EMBO J.* 24, 1277–1286.
- 302 Gasparoto, T.H., Gaziri, L.C., Burger, E., de Almedia, R.S., Felipe, I., 2004.  
303 Apoptosis of phagocytic cells induced by *Candida albicans* and production  
304 of IL-10. *FEMS Immunol. Med. Microbiol.* 42, 219–224.

- Guo, R.F., Ward, P.A., 2005. Role of C5a in inflammatory responses. *Annu.*  
306 *Rev. Immunol.* 23, 821–852.
- Iiyama, K., Hajra, L., Iiyama, M., Li, H., DiChiara, M., Medoff, B.D., Cybulsky,  
307 M.I., 1999. Patterns of vascular cell adhesion molecule-1 and intercellular  
308 adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions  
309 and at sites predisposed to lesion formation. *Corc. Res.* 85, 199–207.
- Ishida-Okawara, A., Kimoto, Y., Watanabe, K., Shibata, M., Masuda, K., Takano,  
311 Y., Kawaguchi, K., Akagawa, H., Nilubol, N., Hotta, K., Yazawa, K., Mizuno,  
312 S., Suzuki, K., 1991. Purification and characterization of aeanostains:  
313 actinomycete-derived fatty acid inhibitors to myeloperoxidase release from  
314 human polymorphonuclear leukocytes. *J. Antibiot.* 44, 524–532.
- Iwai, T., Inoue, Y., Umeda, M., Huang, Y., Kurihara, N., Koike, M., Ishikawa, I.,  
316 Tuite, A., Harakidas, P., Bihun, C., Massie, B., Gros, P., 2004. Dysregulated  
317 inflammatory response to *Candida albicans* in a C5-deficient mouse strain.  
318 *J. Vasc. Surg.* 42, 107–115.
- Muller, J., Melchinger, W., 2004. The significance of *Candida* serology based  
319 on cell wall antigens. *Mycoses* 47, 2–10.
- Mullick, A., Elias, M., Picard, S., Bourget, L., Joveceviski, O., Gauthier, S.,  
321 Tuite, A., Harakidas, P., Bihun, C., Massie, B., Gros, P., 2004. Dysregulated  
322 inflammatory response to *Candida albicans* in a C5-deficient mouse strain.  
323 *Infect. Immun.* 72, 5868–5876.
- Nagi-Miura, N., Shingo, Y., Adachi, Y., Ishida-Okawara, A., Oharaseki, T.,  
325 Takahashi, K., Naoe, S., Suzuki, K., Ohno, N., 2004. Induction of coronary  
326 arteritis with administration of CAWS (*Candida albicans* water-soluble  
327 fraction) depending on mouse strains. *Immunopharmacol. Immunotoxicol.*  
328 26, 527–543.
- Netea, M.G., Stuyt, R.J., Kim, S.H., Van der Meer, J.W., Kullberg, B.J., Dinarello,  
330 C.A., 2002. The role of production of interferon-gamma induced by *Candida*  
331 *albicans* in human whole-blood cultures. *J. Infect. Dis.* 185, 963–970.
- Ohno, N., 2003. Chemistry and biology of angitis inducer: *Candida albicans*  
333 water-soluble mannoprotein-beta-glucan complex (CAWS). *Microbiol.*  
334 *Immunol.* 47, 479–490.
- Spellberg, B.J., Collins, M., French, S.W., Edwards Jr., J.E., Fu, Y., Ibrahim,  
336 A.S., 2005. A phagocytic cell line markedly improves survival of  
337 infected neutropenic mice. *J. Leukocyte Biol.* 78, 338–344.
- Takahashi, M., Koga, M., Yokoyama, K., Yuki, N., 2005. Epidemiology of  
339 *Campylobacter jejuni* isolated from patients with Guillain-Barre and Fisher  
340 syndromes in Japan. *J. Clin. Microbiol.* 43, 335–339.
- Urban, C.F., Reichard, U., Brinkmann, V., Zychlinsky, A., 2006. Neutrophil  
342 extracellular traps capture and kill *Candida albicans* yeast and hyphal  
343 forms. *Cell. Microbiol.* 8, 668–676.
- Villar, C.C., Kashleva, H., Mitchell, A.P., Dongari-Bagtzoglou, A., 2005.  
345 Invasive phenotype of *Candida albicans* affects host proinflammatory  
346 response to infection. *Infect. Immun.* 73, 4588–4595.
- Zupanic-Krmek, D., Nemet, D., 2004. Systemic fungal infections in  
348 immunocompromised patients. *Acta Med. Croat.* 58, 251–261.

Highlighted paper selected by Editor-in-chief

## Beta-Mannosyl Linkages Negatively Regulate Anaphylaxis and Vasculitis in Mice, Induced by CAWS, Fungal PAMPs Composed of Mannoprotein–Beta-Glucan Complex Secreted by *Candida albicans*

Hiroyasu SHINOHARA,<sup>a</sup> Noriko NAGI-MIURA,<sup>a</sup> Ken-ichi ISHIBASHI,<sup>a</sup> Yoshiyuki ADACHI,<sup>a</sup> Akiko ISHIDA-OKAWARA,<sup>b</sup> Toshiaki OHARASEKI,<sup>c</sup> Kei TAKAHASHI,<sup>c</sup> Shiro NAOE,<sup>c</sup> Kazuo SUZUKI,<sup>b</sup> and Naohito OHNO\*<sup>a</sup>

<sup>a</sup>Laboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Science; 1432-1, Horinouchi, Hachioji, Tokyo 192-0392, Japan; <sup>b</sup>Department of Bioactive Molecules, National Institute of Infectious Diseases; Tokyo 162-8640, Japan; and <sup>c</sup>Department of Pathology, Ohashi Hospital, Toho University School of Medicine; Tokyo 153-8515, Japan.

Received April 19, 2006; accepted June 22, 2006; published online June 23, 2006

*Candida albicans* water soluble fraction (CAWS) is a water-soluble extracellular mannoprotein–beta-glucan complex obtained from the culture supernatant of *Candida albicans*, which grows in a chemically defined medium. CAWS induced toxic reactions, such as acute anaphylactoid reaction, by intravenous administration and coronary arteritis by intraperitoneal administration. To clarify the structure responsible for these toxic reactions, *C. albicans* was cultured in pH- and temperature-controlled conditions and prepared with CAWS with or without the beta-1,2-linked mannosyl segment (BM). The structure of CAWS was assessed by immunochemical and spectroscopic methodologies, and we found that CAWS prepared under the natural culture conditions contained only small amounts of BM and CAWS prepared at neutral conditions at 27 °C contained a significantly higher percentage of BM. Both the acute lethal toxicity and coronary arteritis induction was significantly more severe in the absence of BM. Activation of a complement pathway, the lectin pathway, by CAWS was significantly stronger in the absence of BM. These facts strongly suggest that BM linkages in CAWS negatively modulate acute and chronic toxicity of CAWS, and may be strongly related to the lectin pathway of the complement activation.

**Key words** *Candida albicans*; arteritis; mannoprotein; beta-1,2-mannan; DBA/2 mice

*Candida* spp. is a medically important fungus that frequently induces deep mycosis and fungemia, especially in immunocompromised hosts.<sup>1)</sup> Pathogenic microbes have various toxic mechanisms that are unique to each species and are essential for survival and evolution. Pathogenic mechanisms of eukaryotic microbes are complicated compared to those of bacteria and viruses. Although there have been extensive basic and clinical studies, the major pathogenic factors for *Candida* spp. are still unknown and precise characterization of each of the constituents would be valuable.

Cardiovascular disease is one of the most life-threatening diseases, and various new compounds and new methods of pharmaceutical care, such as gene therapy and drug delivery systems, have been developed to treat it. There are several lines of evidence suggesting that inflammatory cells, particularly macrophages and neutrophils, regulate endothelial cell function and dysfunction in atherosclerosis, via the release of mediators that display proinflammatory activity. Analysis of such diseases by animal models will give promising feedback to human health.

Murata *et al.*<sup>2)</sup> reported that Kawasaki-disease-like coronary arteritis was induced in mice by administration of an alkaline extract of *C. albicans* (CADS) isolated from patients with Kawasaki disease (KD). KD, a disease of unknown cause that mainly affects children aged 4 and under, was first reported by Kawasaki in 1967.<sup>3)</sup> The patient presents with systemic coronary arteritis in nearly 10% of cases. Although the occurrence of such coronary artery disorders has decreased with  $\gamma$ -globulin therapy, the mechanism of occurrence along with the pharmacological mechanism of treat-

ment is unknown.<sup>4)</sup> Murata's murine model has been extensively examined from various points of view, e.g. anti-myeloperoxidase antibody production, susceptibility loci, and histopathological features.<sup>5,6)</sup>

Previously, we prepared a water-soluble polysaccharide fraction of *C. albicans* released into a culture supernatant (*Candida albicans* water-soluble fraction: CAWS) and performed various analyses.<sup>7–10)</sup> The most important point concerning this system is that we use a completely synthetic medium, named C-limiting medium, to eliminate contaminants from the culture medium, such as endotoxins, peptidoglycans, and nucleic acids. Series of our studies found that CAWS shows various toxic activities, such as cytokine synthesis by leukocytes, platelet aggregation, lethal toxicity, enhancement of side effect of indomethacin, induction of coronary arteritis in mice, and so on. Thus, CAWS may be a pathogen-associated microbial product (PAMPs) of *Candida albicans*.

In a previous study we found that intraperitoneal administration of CAWS to mice induces coronary arteritis similar to that induced by CADS.<sup>8–10)</sup> It is of note that CAWS-induced arteritis showed significant strain dependency: The incidence of arteritis was 100% in C57BL/6, C3H/HeN and DBA/2 mice, but only 10% in CBA/J mice. The coronary arteritis observed in DBA/2 mice was the most serious, with the majority of mice expiring during the observation period.

The coronary arteritis induced by CAWS was accompanied by hypertrophy of the tunica intima, the rupture of elastic fibers and a diffuse invasion by lymphocytes, histiocytes, fibroblasts, smooth muscle cells and eosinophils of vascular

\* To whom correspondence should be addressed. e-mail: ohnonao@ps.toyaku.ac.jp

endothelial cells and the regions surrounding blood vessels. Based on such characteristics, the coronary arteritis induced by CAWS was presumed to be proliferative granulomatous coronary arteritis, and is clearly different from fibrinoid arteritis. In DBA/2 mice, it was observed to cover nearly the entire periphery of the vessels, and those mice were considered to demonstrate the most virulent form of coronary arteritis.

Structure of yeast cell wall, such as in *Saccharomyces cerevisiae*, *Candida albicans*, and *Schizosaccharomyces pombe*, have been extensively examined and it was found that the overall structure is quite complex and regulated by expression of multiple genes.<sup>11,12</sup> According to the results of NMR and biochemical analyses, CAWS was found to be composed of a mannoprotein and  $\beta$ -glucan portion, which are the main components of the *C. albicans* cell wall.<sup>8</sup> The mannoprotein region of *Candida albicans* is composed of both *N*- and *O*-glycosyl linkages with alfa- and beta-linked mannosyl residues.<sup>13,14</sup> Phosphodiester linkages are also included. Mannan synthesis is regulated by several specific glycosyl transferases.<sup>15–17</sup> It is also an immunochemical determinant of *Candida* spp.<sup>18,19</sup> It is of note that the structure of mannan is modulated by various culture conditions, such as temperature and pH.<sup>20,21</sup> The structure of mannan is also known to be modulated by various stresses. The structure of mannan is a key molecule for recognition of *Candida* by host biodefense system and might be strictly regulated by the affinity for specific receptors. Analysis of the disease from the structural point of view is an indispensable study.

In a preliminary experiment, the pH of a culture medium was measured and it was found that shifted from 5.2 to 2.3 at the end. In the present study, we have prepared CAWS using different culture conditions and examined CAWS-induced anaphylactoid reaction and vasculitis. We demonstrated that beta-1,2-mannosyl linkages are the negative regulators for both anaphylactoid reaction and vasculitis.

## MATERIALS AND METHODS

**Mice** Male ICR and DBA/2 mice were purchased from Japan SLC. The mice were housed in a specific pathogen-free (SPF) environment and were used in the study at 5 weeks of age. All animal experiments were followed by the guideline of laboratory animal experiments in Tokyo University of Pharmacy and Life Sciences (TUPLS), and each of the experimental protocol was approved by the committee of laboratory animal experiments in TUPLS.

**Preparation of CAWS** *Candida albicans* strain IFO1385 was purchased from the Institute for Fermentation, Osaka (IFO), stored at 25 °C on Sabouroud's agar (Difco, U.S.A.) and passaged once every three months. CAWS was prepared from *C. albicans* strain IFO1385 in accordance with conventional methods.<sup>7,9,10</sup> The procedure used was as follows: 5 l of medium (C-limiting medium) was added to a glass incubator and cultured for 2 d at 27 °C with air supplied at a rate of 5 l/min and rotation at 400 rpm. Following the culture, an equal volume of ethanol was added and after the mixture was allowed to stand overnight, the precipitate was collected. The precipitate was dissolved in 250 ml of distilled water, ethanol was added and the mixture was allowed to stand overnight. The precipitate was collected and dried with

acetone to obtain CAWS.

**Administration Schedule for Induction of Coronary Arteritis (10)** CAWS (4 mg/mouse) was administered intraperitoneally for 5 consecutive days to each mouse in week 1. At week 5, the hearts of the animals were fixed with 10% neutral formalin and prepared in paraffin blocks. Tissue sections were stained with hematoxylin–eosin (HE) stain.

**ELISAs of *Candida* Typing Sera to CAWS** The reactivity of CAWS to serum factors from *Candida* that consists of rabbit polyclonal antibodies against *Candida* cell wall mannan was detected by ELISA. A solution of CAWS in 50 mM carbonate buffer (pH 9.6) was coated onto Nunc immunoplates, which were then incubated at 4 °C overnight. The plates were washed extensively with 0.05% Tween 20 containing PBS (PBST); unbound sites were blocked by the addition of 1% BSA containing PBST (BPPBST) to wells for 40 min at 37 °C and then the wells were washed 6 times with PBST. *Candida* serum factors serially diluted with BPPBST were added, and incubated for 60 min at 37 °C. After 6 washes with PBST, the wells were treated with peroxidase-conjugated goat anti-rabbit IgG and the 3,3',5,5'-tetramethylbenzidine microwell peroxidase substrate system (TMB; KPL inc). After 45 min, the reaction was stopped with 1 N H<sub>3</sub>PO<sub>4</sub>, and then the optical density of each well was read at 450 nm on an automatic microplate reader.

**Measurement of Complement Activation** The complement kit for assessment of classical, alternative and MBL pathway activity was developed by the EU consortium and is now commercially available (Wielisa COMPL300 Total Complement Functional Screen kit from Wieslab AB, Lund, Sweden). The kit was operated by the instructions provided in the manual with slight modifications. In brief, strips of wells for classical pathway (CP) evaluation were precoated with IgM, strips for alternative pathway (AP) determination were coated with LPS, and mannan binding lectin (MBL) pathway (MBL-P) strips were coated with mannan. Sera were diluted 1/101 for the CP and MBL-P assay and 1/18 for the AP assay in specific buffers, serial dilutions of CAWS solution was added to the diluted sera and incubated. The resulting sera were added to the strips of the kit and were incubated for 1 h at 37 °C. After washing the strips, alkaline phosphatase-conjugated antihuman C5b-9 was added and incubated at room temperature for 30 min. Additional washing was performed, substrate was added, and the wells were incubated for 30 min. Finally, absorbance values were read at 405 nm. In each assay, standard positive and negative control sera provided in the kit as lyophilised material were reconstituted with distilled water. Complement activity was calculated using the following formula: activity = 100% × (mean A405 (sample) – mean A405 (negative control)) / (mean A405 (standard serum) – mean A405 (negative control)). Samples as well as standard serum and negative control serum were tested in duplicate at a fixed dilution.

**Assay for Anaphylactoid Reaction** Indicated dose of CAWS solution was i.v. administered to ICR mice. The incidence and the severity of the rapid anaphylactoid shock were assessed within 30 min. For measuring tolerance, low dose CAWS was i.v. administered to ICR mice 1 h prior to induce anaphylactoid reaction by CAWS (400  $\mu$ g/mouse).

**NMR Spectroscopy** <sup>1</sup>H-NMR experiments were performed with a Bruker DPX 400 equipped with XWIN-NMR

software. The spectra were recorded using a solution of each soluble fraction (10 mg/ml) in D<sub>2</sub>O at 45 °C with acetone as an internal standard.

RESULTS

Preparation of CAWS by Various Culture Conditions

Figure 1 shows the data of pH monitoring during *Candida* culture in C-limiting medium. The data clearly demonstrated that at pH uncontrolled natural time course, pH was 5.2 at the beginning and was lowered to around 2 at the end, thus the naturally expressed CAWS was produced in this culture condition. In order to prepare CAWS with modulated mannan structure, *C. albicans* IFO1385 was cultured at either 27 °C or 37 °C in C-limiting medium. In addition, pH of the culture medium was controlled at either pH 2.3, 5.2, or 7.0 by automatically added sodium hydroxide solution. The extracellular mannoprotein fraction was prepared by a previously established procedure that was the same as naturally produced CAWS. The names of each fraction were designated as CAWS 27-2.3, CAWS 27-5.2, CAWS 27-7.0, CAWS 37-2.3, CAWS 37-5.2, and CAWS 37-7.0. The name of CAWS prepared at natural pH course was designated as 27(-) and 37(-), respectively. In addition, CAWS prepared at 27 °C was designated as CAWS 27s which include 27-2.3, 27-5.2, 27-7.0, and 27(-), and prepared at 37 °C as CAWS 37s which include 37-2.3, 37-5.2, 37-7.0, and 37(-). Yield and some parameters of each CAWS are shown in Table 1. The structure of the mannan moiety was characterized by the reactivity to the typing sera and NMR spectral analysis.




Fig. 1. Monitoring pH of *C. albicans* IFO1385 Culture in C-Limiting Medium at 27 °C

One hundred milliliters of *C. albicans* IFO1385 precultured in liquid to logarithmic phase was added to 4l of C-limiting medium in a jar fermenter with 41 air/min and 400 rpm stirring. The pH of the culture medium was measured automatically with a pH meter.

Figure 2 shows relative reactivity to the typing sera no. 5, 6, and 11. Experiments were done using three doses of CAWS solution adsorbed onto the ELISA plates. The pattern of reactivity of each CAWS preparation to the sera were similar between no. 5 and no. 6. In contrast, reactivity to no. 11 was significantly different. In the cases of no. 5 and no. 6, comparing the dose to show absorbance 1.0, reactivity of CAWS 27-5.2 and CAWS 27-7.0 was significantly increased compared to CAWS 27(-), and other preparations. In contrast, relative activity of CAWS 27-5.2 and CAWS 27-7.0




Fig. 2. Reactivity of CAWS Prepared under Various Conditions to *Candida* Typing Sera no. 5, 6, and 11

Each 25, 2.5, or 0.25 μg/ml solution of CAWS was adsorbed on ELISA plate and diluted typing sera was added. After appropriate incubation time, plate-bound antibody was measured by peroxidase conjugated anti-rabbit IgG with TMB reagent. (A) Anti no. 5; (B) anti no. 6; (C) anti no. 11.

Table 1. Properties of CAWS Prepared by Various Culture Conditions

CAWS	Yield (mg/l)	Cell (g/l)	C (%)	H (%)	N (%)	Factor G	Factor C
27(-)	147±30	4.3±0.7	30.1±2.7	5.5±0.4	1.6±0.3	—	<2
27-2.3	132±19	4.0±0.2	27.5±4.7	5.0±0.7	1.6±0.1	0.73±0.57	0.25±0.1
27-5.2	247±26	3.5±0.4	28.6±3.5	5.2±0.4	2.8±0.3	ND	0.33±0.45
27-7.0	381±77	3.4±0.1	18.1±5.3	4.0±0.8	2.1±0.6	ND	0.71±0.73
37(-)	84±33	2.0±0.7	26.5±1.8	4.8±0.4	1.1±0.1	1.24±0.21	0.03±0.02
37-2.3	160±17	3.3±0.1	18.5±9.1	3.7±1.5	1.1±0.2	0.56±0.16	ND
37-5.2	255±87	3.0±0.2	20.3±2.7	4.0±0.7	0.9±0.2	ND	0.1±0.03
37-7.0	263±12	3.2±0.5	24.3±1.1	4.9±0.1	1.5±0.1	0.07±0.01	0.08±0.01

27(-); cultured at 27 °C without pH control, 27-2.3; cultured at 27 °C and pH was maintained at 2.3, 27-5.2; cultured at 27 °C and pH was maintained at 5.2, 27-7.0; cultured at 27 °C and pH was maintained at 7.0, cell; yield of dried cells. C, H, N; elemental analysis (carbon, hydrogen, nitrogen), factor G; content of 1,3-beta-glucan (ng/ml), factor C; content of endotoxin (ng/ml), ND; not detected.




Fig. 3. Proton-NMR Spectra of CAWS in D<sub>2</sub>O

(A) CAWS 27s prepared from the 27°C culture. (B) CAWS 37s prepared from the 37°C culture. Arrow indicates signals corresponding to beta-1,2-mannosyl linkages.

was significantly decreased in the case of typing sera no. 11. It is proposed that the specific epitope of no. 5 and no. 6 are for the beta-1,2-linked manno-oligosaccharides, and no. 11 for the alpha-1,2 and 1,6-manno-oligosaccharides.<sup>20,21</sup> These data strongly suggested that CAWS 27-5.2 and CAWS 27-7.0 contained significantly higher concentration of beta-1,2-linkages and reduced concentration of alpha-linkages.

Figure 3 shows NMR spectra of CAWS preparations. Each of the spectra contained many signals in the anomeric region (4.8–5.5), and thus, we could not do complete assessment at this time. However, comparing the published spectra of the cell wall mannan moiety of *Candida* spp. by Professor Suzuki *et al.*,<sup>20,21</sup> major signals could be assigned. Chemical

Table 2. Anaphylactoid Reaction Induced by CAWS Prepared under Various Conditions

CAWS	3200	800	200	50	12.5
27(-)			3/3	0/3	
27-2.3			3/3	0/3	
27-5.2	2/3	0/3	0/3		
27-7.0	0/3	0/3	0/3		
37(-)			2/3	1/3	0/3
37-2.3			3/3	1/3	0/3
37-5.2			2/3	0/3	
37-7.0			2/3	0/3	

Indicated dose ( $\mu\text{g}/\text{mouse}$ ) of CAWS was i.v. administered to mice ( $n=3$ ). Lethality of each mouse was monitored 30 min later. \*/\*, number of mice, dead/total.

shift around 4.85, shown as arrow in the spectra, would be beta-linked manno-oligosaccharides. The signal around 4.85 was only detected in the spectra of CAWS 27-5.2 and CAWS 27-7.0. Signals around 5.13 also appeared in those spectra would be the residues linked to beta-mannosyl linkages. In contrast, signals around 5.05 which include alpha-mannose residues was reduced in relation to the substitution of beta-mannosyl linkages. It is of note that even in the same pH conditions, CAWS 37-5.2 and CAWS 37-7.0 did not show such signals, and this observation was strongly supported by immunochemical reactivity. NMR spectra of CAWS 37(-), CAWS 37-2.3, CAWS 37-5.2, and CAWS 37-7.0, shown in Fig. 3b show simple anomeric signals compared to those of CAWS 27s. Shibata *et al.* examined the cell wall mannan structure of *Candida parapsilosis* and *Candida albicans* by use of controlled hydrolysis and NMR spectroscopy.<sup>22</sup> Comparing Proton NMR spectra of *C. parapsilosis* and *C. albicans*, that of *C. parapsilosis* is simple and shows only 5 major signals in the anomeric region of 1D-NMR spectrum. Those signals correspond to alpha mannosyl linkages. At least in 1D-NMR spectrum, CAWS 37s resembles that of *C. parapsilosis*, also supporting that beta-1,2-linkages are missing in CAWS 37s. Regulation of beta-1,2-mannosyl linkages by culture condition is also reported in *Candida guilliermondii*.<sup>23</sup> From the data of immunochemistry and NMR spectra, CAWS 27-5.2 and CAWS 27-7.0 contained significantly higher concentrations of beta-1,2-linked manno-oligosaccharides.

**Acute Toxicity of CAWS Prepared by Various Culture Conditions** We have previously shown that CAWS induced acute anaphylactoid reaction, similar to *E. coli* O9 LPS and yeast mannan.<sup>24,25</sup> We compared acute anaphylactoid reaction of various CAWS preparations. As shown in Table 2, various concentrations of CAWS were intravenously administered to ICR mice and survival within 30 min was compared. In this experiment, the majority of CAWS preparations induced almost complete lethal toxicity at doses of 200  $\mu\text{g}/\text{mouse}$ . However, CAWS 27-5.2 required 3200  $\mu\text{g}$  for lethal toxicity and CAWS 27-7.0 did not show any lethal toxicity in this experimental condition. These facts strongly suggested beta-1,2-linked manno-oligosaccharide would be a negative regulator for acute anaphylactoid reaction. To confirm the possibility, tolerance induction by CAWS preparations was also tested. As shown in Table 3, administration of 16  $\mu\text{g}$  of CAWS 27(-) and CAWS 27-2.3 significantly reduced lethality of subsequent high dose CAWS administration. However, in the case of CAWS 27-5.2, a relatively

Table 3. Tolerance Induction in CAWS Induced Anaphylactoid Reaction by Pretreatment with CAWS Prepared under Various Conditions

CAWS	64	16	4	1
27(-)		1/3	3/3	
27-2.3		0/3	2/3	2/3
27-5.2	0/3	2/3	2/3	

Indicated dose of CAWS ( $\mu\text{g/ml}$ ) was i.v. administered to mice ( $n=3$ ). CAWS(-) was again i.v. administered to each mouse, and lethality was monitored 30 min later. \*/\*, number of mice, dead/total.




Fig. 4. Complement Activation by CAWS

(A) Screening of classical (CP), lectin (MP), and alternative (AP) pathway of complement activation by CAWS. (B) Dose response of CAWS-induced activation of the lectin pathway of complement. CAWS 27(-) and CAWS 27-7.0 were used in this experiment. PC; positive control serum, NC; negative control serum.

higher dose, 64  $\mu\text{g}$ , was required for tolerance induction. This result also strongly suggested that beta-1,2-mannooligosaccharides negatively modulate acute lethal toxicity of CAWS.

Complement activation and the resulting anaphylactic peptides, C3a and C5a, production are the most commonly postulated mechanism for acute toxicity. In the preliminary experiments, incubation of CAWS with human sera produced high concentration of C5a anaphylatoxic peptide. Because of the difficulty in measuring mouse complement activation, we used a commercially available kit for human complement activation in the present study. Activity of classical, lectin, and alternative pathways were measured using IgM, mannan, and LPS-coated ELISA plate and specific reaction buffer systems. As shown in Fig. 4a, CAWS of 20 to 2000  $\mu\text{g/ml}$  were added, and it was found that CAWS activated complement was almost specifically mediated by the lectin pathway. In this dose range, CAWS 27(-) and CAWS 27-7.0 did not show any differences; however, comparing the activity be-




Fig. 5. Histological Analysis of DBA/2 Mice Administered with CAWS

CAWS prepared under various conditions (4 mg/mouse) was administered i.p. to DBA/2 mice for five consecutive days. Five weeks later, the aorta with coronary of these mice were stained with hematoxylin-eosin.

tween doses of 20 ng and 200 ng shown in Fig 4b, CAWS 27(-) showed almost ten times higher activity than CAWS 27-7.0. These results strongly suggest that beta-1,2-linked manno-oligosaccharides inhibited complement activation by alpha-linked mannose residues.

**Arteritis Induction by CAWS Prepared by Various Culture Conditions** Intraperitoneal injection of CAWS induced coronary arteritis in mice.<sup>8-10</sup> Severity is significantly dependent on strains of mice and DBA/2 shows the most severe reaction, resulting in death. Coronary arteritis induction by CAWS prepared as above was compared. CAWS was administered i.p. to each mouse at 4 mg/mouse for 5 consecutive days and sections of coronary artery were prepared at 4 weeks after the final CAWS administration. Figures 5 to 8 show hematoxylin eosin staining of aorta, aortic valve, and the coronary artery in CAWS-administered mice. CAWS prepared by the standard protocol induced strong inflammation in this area. CAWS 27-2.3, CAWS 37(-), CAWS 37-2.3, CAWS 37-5.2, and CAWS 37-7.0 show similar inflammation. However, CAWS 27-5.2 and CAWS 27-7.0, both of which contained higher content of beta-1,2-manno-oligosaccharides, show significantly weaker inflammation. The histology of the aorta, aortic valve, and coronary artery using higher magnification (Figs. 7, 8) shows similar phenotypes.

Coronary arteritis was also examined by survival. As shown in Fig. 9, almost all of the mice that had CAWS administered died except for CAWS 27-5.2, in which only one mouse out of five died. Figure 10 shows the dose response of survival and corresponding histology of DBA/2 mice administered CAWS 27(-). Arteritis was induced even with 250  $\mu\text{g/mouse}$  administration and 2/5 mice died in this condition. Considering the data of survival and histology of CAWS 27(-) and CAWS 27-5.2, the relative activity of






Fig. 6. Comparison of Histology of Aorta in DBA/2 Mice Administered Native and pH-Controlled CAWS

CAWS 27(-), CAWS 27-5.2, CAWS 37(-), CAWS 37-5.2 (4 mg/mouse) were administered i.p. to DBA/2 mice for five consecutive days. Five weeks later, the aorta with coronary of these mice were stained with hematoxylin-eosin.




Fig. 8. Comparison of Histology of Coronary Artery in DBA/2 Mice Administered Native and pH-Controlled CAWS

CAWS 27(-), CAWS 27-5.2, CAWS 37(-), CAWS 37-5.2 (4 mg/mouse) were administered i.p. to DBA/2 mice for five consecutive days. Five weeks later, the artery with coronary of these mice were stained with hematoxylin-eosin.




Fig. 7. Comparison of Histology of Cusp Region of Coronary Artery in DBA/2 Mice Administered Native and pH-Controlled CAWS

CAWS 27(-), CAWS 27-5.2, CAWS 37(-), CAWS 37-5.2 (4 mg/mouse) were administered i.p. to DBA/2 mice for five consecutive days. Five weeks later, the aorta with coronary of these mice were stained with hematoxylin-eosin.




Fig. 9. Survival Time of CAWS-Administered Mice

CAWS 27s and CAWS 37s (4 mg/mouse) was administered i.p. to DBA/2 mice for five consecutive days in the 1st week. Survival was observed for 12 weeks.

CAWS 27(-) was at least 20 times higher than that of CAWS 27-5.2. From these findings, CAWS with beta-1,2-linked manno oligosaccharides showed significantly weaker inflammatory reaction in this experimental model.




Fig. 10. Dose Response of Survival Time of CAWS-Administered Mice

CAWS 27(-) (0.25, 1, or 4 mg/mouse) was administered i.p. to DBA/2 mice for five consecutive days in the 1st week. Survival was observed for 9 weeks. Hematoxylin-eosin stain of the aorta with coronary were also shown.

## DISCUSSION

*Candida albicans* is a clinically important fungus and is known to cause disseminated candidiasis and candidemia in immunocompromised hosts. Patients with deep mycoses, such as that induced by *C. albicans* and *A. fumigatus*, have been demonstrated to release  $\beta$ -glucans into the blood. However, these are present in extremely small amounts, and the overall structure of the factor G activating substance present in the blood is unknown.<sup>26)</sup> The factor G activating substance has the potential to exhibit various biological activities, but the details of this are also unknown. In order to clarify these matters, we first cultured *C. albicans* in a completely synthetic medium in order to obtain water-soluble limulus factor G activating substance that is released from the cells, and obtained a water-soluble polysaccharide fraction released into the culture supernatant (CAWS), which is thought to be similar to the  $\beta$ -1,3-D-glucan actually present in patient blood.<sup>8)</sup> Murata *et al.* conducted an analysis on children with KD and found that *C. albicans* extract (CADS) isolated from the stool specimens of the patients induced coronary angiitis in mice that resembled KD.<sup>5,6)</sup> During the course of joint research, we found that administration of CAWS according to this protocol induced a similar coronary angiitis in mice.<sup>8-10)</sup>

In the present study, the relationship between culture conditions of *Candida* and induction of some of the pathologic parameters, such as acute shock, arteritis, and complement activation, was examined, and the condition producing beta-1,2-linkage significantly reduced all three parameters measured in the present study. It is of note that in the standard culture medium, C-limiting medium, the pH was acidified during culture. Thus, in the present study we have prepared CAWS in significantly regulated conditions and we analyzed both activity and structure. We have confirmed that CAWS prepared under the condition of neutral at 27°C culture significantly reduced activity and is strongly related to the presence of beta-1,2-mannosyl linkages. These facts clearly

demonstrated that beta-1,2-linkages are negative regulators for pathologic parameters, such as acute shock, arteritis, and complement activation. At this time, the role of beta-1,2-linkages on the anaphylactoid reaction and arteritis induction could not be fully clarified. As shown in Table 3, pretreatment of mice with CAWS 27-5.2 induced tolerance in the CAWS-induced anaphylactoid reaction, but this was less than that observed with CAWS 27(-) and CAWS 27-2.3. In addition, small numbers of beta-1,2-linkages are present in CAWS 27(-), which is comparable arteritis to CAWS 27-2.3. These facts strongly suggest that beta-1,2-linkages cover the active site, the alpha mannan moiety, of CAWS. Beta-1,2-linkage itself might not show receptor-mediated, specific and negative regulatory reactions.

Acute anaphylactoid reaction is known to be induced by lipopolysaccharide from *E. coli* O9 (O9 LPS), which possesses the mannose homopolysaccharide as the O-antigen region.<sup>25)</sup> Very recently, we compared immunotoxicological and immunochemical similarity between CAWS and O9 LPS.<sup>24)</sup> CAWS strongly reacted with *Candida* serum factors, and the reactivity was found to be partially competed with O9 LPS. CAWS-induced anaphylactoid reaction was inhibited by pretreatment of mice with i.p. injection of CAWS. The lethality was found to be inhibited by i.v. injection of O9 LPS. *Vice versa*, O9 LPS-induced acute anaphylactoid reaction in muramyl-dipeptide primed mice was also inhibited by pretreatment of mice with CAWS. These results suggested that CAWS and O9 LPS from gram-negative bacteria share, at least in part, immunochemical and immunotoxicological activities.

Mannose binding lectin (MBL) is a key molecule for innate immune response.<sup>27)</sup> Neth *et al.* analyzed the concentration of MBL in various inbred strains and found that all of the strains tested contained MBL.<sup>28)</sup> The MBL-A and MBL-C levels in 10 laboratory mice strains were 4 to 12  $\mu$ g/ml, and 16 to 118  $\mu$ g/ml, respectively. Higher concentration of MBL was detected in patients of rheumatic heart disease.<sup>29)</sup> Point mutation in MBL is also related to severe atherosclerosis.<sup>30)</sup> In the present study, we have shown contribution of the complement lectin pathway for the initiation of CAWS-induced anaphylactoid reaction and arteritis. We did not measure concentration of each complement components, and concentration of each component in inbred strains might be related to the phenotype of anaphylactoid reaction and arteritis.

The anaphylatoxin receptor is a family of G-protein coupled receptors (G-PCR).<sup>31)</sup> It is well known that signaling of G-PCR induced cross talk and cross desensitization.<sup>32)</sup> Cross desensitization of C5a receptor was reported with receptors of fMLP, IL-8, LTB<sub>4</sub> and so on. Exaggerated inflammatory phenotype of bleomycin-induced lung fibrosis was shown in C5 knockout mice. DBA/2 is a strain deficient in C5. Severity of arteritis might be related to cross desensitization and may follow anti-inflammatory action of C5a receptor mediated signaling.

In the series of studies, we have analyzed CAWS-induced arteritis from various points of view. The most striking result was the significant strain dependency of arteritis as well as acute anaphylactoid reaction. For example, C3H/HeN is the most sensitive strain for anaphylactoid reaction but arteritis is moderate. DBA/2 is completely resistant to anaphylactoid reaction but shows the most severe arteritis. CBA/J is the

most resistant strain for arteritis but induced anaphylactoid reaction (unpublished results). B6 is sensitive to both anaphylactoid reaction and arteritis. These facts strongly suggest that the genes responsible for anaphylactoid reaction and arteritis would be at least in part different, and thus regulated by multiple genetic factors. However, from the point of early signaling events, activation of the lectin pathway of the complement by alpha-mannan moiety of CAWS might be key for both of the activities. Several reports indicated that *Candida albicans* could bind to MBL.<sup>27,28)</sup>

We have shown that CAWS-induced arteritis and anaphylactoid reaction is dependent on strains of mice. In the present study, we demonstrated the essential structure to induce arteritis and anaphylactoid reaction. Strain specificity of both reactions was independent. We also analyzed the kinetics of arteritis induction and determined that it is separated into at least three phases, *i.e.*, early, middle, and late.<sup>10)</sup> In the early phase, a variety of biochemical events is induced. In the middle phase, remodeling of arteries is induced. In the late phase, arteritis and coronary arteritis stressed heart function, resulting in cardiomegaly. Undoubtedly, multiple genes are involved in arteritis and cardiomegaly. This model proved very useful for analyzing whole steps of cardiac diseases.

**Acknowledgements** This work was partly supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and The Promotion and Mutual Aid Corporation for Private Schools, Japan. Also supported by Ministry of Health, Labour and Welfare in Japan a Grant on "Research on Regulatory Science of Pharmaceuticals and Medical Devices."

## REFERENCES

- 1) Shoham S., Levitz S. M., *Br. J. Haematol.*, **129**, 569—582 (2005).
- 2) Murata H., Iijima H., Naoe S., Atobe T., Uchiyama T., Arakawa S., *Jpn. J. Exp. Med.*, **57**, 305—313 (1987).
- 3) Kawasaki T., Kosaki F., Okawa S., Shigematsu I., Yanagawa H., *Pediatrics*, **54**, 271—276 (1974).
- 4) Furusho K., Kamiya T., Nakano H., Kiyosawa N., Shinomiya K., Hayashidera T., Tamura T., Hirose O., Manabe Y., Yokoyama T., *Lancet*, **2**, 1055—1058 (1984).
- 5) Oharaseki T., Kameoka Y., Kura F., Persad A. S., Suzuki K., Naoe S., *Microbiol. Immunol.*, **49**, 181—189 (2005).
- 6) Takahashi K., Oharaseki T., Wakayama M., Yokouchi Y., Naoe S., Murata H., *Inflamm. Res.*, **53**, 72—77 (2004).
- 7) Kurihara K., Shingo Y., Miura N. N., Horie S., Usui Y., Adachi Y., Yadomae T., Ohno N., *Biol. Pharm. Bull.*, **26**, 233—240 (2003).
- 8) Ohno N., *Microbiol. Immunol.*, **47**, 479—490 (2003).
- 9) Nagi-Miura N., Shingo Y., Adachi Y., Ishida-Okawara A., Oharaseki T., Takahashi K., Naoe S., Suzuki K., Ohno N., *Immunopharmacol. Immunotoxicol.*, **26**, 527—543 (2004).
- 10) Nagi-Miura N., Harada T., Shinohara H., Kurihara K., Adachi Y., Ishida-Okawara A., Oharaseki T., Takahashi K., Naoe S., Suzuki K., Ohno N., *Atherosclerosis*, **186**, 310—320 (2006).
- 11) Poulain D., Jouault T., *Curr. Opin. Microbiol.*, **7**, 342—349 (2004).
- 12) Masuoka J., *Clin. Microbiol. Rev.*, **17**, 281—310 (2004).
- 13) Bates S., Hughes H. B., Munro C. A., Thomas W. P., Maccallum D. M., Bertram G., Atrih A., Ferguson M. A., Brown A. J., Odds F. C., Gow N. A., *J. Biol. Chem.*, **281**, 90—98 (2006).
- 14) Arroyo-Flores B. L., Calvo-Mendez C., Flores-Carreón A., Lopez-Romero E., *FEMS Immunol. Med. Microbiol.*, **45**, 429—434 (2005).
- 15) Rouabhia M., Schaller M., Corbucci C., Vecchiarelli A., Prill S. K., Giasson L., Ernst J. F., *Infect. Immun.*, **73**, 4571—4580 (2005).
- 16) Munro C. A., Bates S., Buurman E. T., Hughes H. B., Maccallum D. M., Bertram G., Atrih A., Ferguson M. A., Bain J. M., Brand A., Hamilton S., Westwater C., Thomson L. M., Brown A. J., Odds F. C., Gow N. A., *J. Biol. Chem.*, **280**, 1051—1060 (2005).
- 17) Suzuki A., Takata Y., Oshie A., Tezuka A., Shibata N., Kobayashi H., Okawa Y., Suzuki S., *FEBS Lett.*, **373**, 275—279 (1995).
- 18) Jones J. M., *Clin. Microbiol. Rev.*, **3**, 32—45 (1990).
- 19) Fukazawa Y., Shinoda T., Tsuchiya T., *J. Bacteriol.*, **95**, 754—763 (1968).
- 20) Kobayashi H., Takahashi S., Shibata N., Miyauchi M., Ishida M., Sato J., Maeda K., Suzuki S., *Infect. Immun.*, **62**, 968—973 (1994).
- 21) Okawa Y., Goto K., Nemoto S., Akashi M., Sugawara C., Hanzawa M., Kawamata M., Takahata T., Shibata N., Kobayashi H., Suzuki S., *Clin. Diagn. Lab. Immunol.*, **3**, 331—336 (1996).
- 22) Shibata N., Ikuta K., Imai T., Satoh Y., Satoh R., Suzuki A., Kojima C., Kobayashi H., Hisamichi K., Suzuki S., *J. Biol. Chem.*, **270**, 1113—1122 (1995).
- 23) Okawa Y., Oikawa S., Suzuki S., *Biol. Pharm. Bull.*, **29**, 388—391 (2006).
- 24) Tada R., Nagi-Miura N., Adachi Y., Ohno N., *Biol. Pharm. Bull.*, **29**, 240—246 (2006).
- 25) Zhao L., Ohtaki Y., Yamaguchi K., Matsushita M., Fujita T., Yokochi T., Takada H., Endo Y., *Blood*, **100**, 3233—3239 (2002).
- 26) Miyazaki T., Kohno S., Mitsutake K., Maesaki S., Tanaka K., Ishikawa N., Hara K., *J. Clin. Microbiol.*, **33**, 3115—3118 (1995).
- 27) Ip W. K., Lau Y. L., *J. Infect. Dis.*, **190**, 632—640 (2004).
- 28) Neth O., Jack D. L., Dodds A. W., Holzel H., Klein N. J., Turner M. W., *Infect. Immun.*, **68**, 688—693 (2000).
- 29) Schafrański M. D., Stier A., Nisihara R., Messias-Reason I. J., *Clin. Exp. Immunol.*, **138**, 521—525 (2004).
- 30) Hegele R. A., Ban M. R., Anderson C. M., Spence J. D., *J. Investig. Med.*, **48**, 198—202 (2000).
- 31) Richardson R. M., Ali H., Tomhave E. D., Haribabu B., Snyderman R., *J. Biol. Chem.*, **270**, 27829—27833 (1995).
- 32) Addis-Lieser E., Kohl J., Chiaramonte M. G., *J. Immunol.*, **175**, 1894—1902 (2005).

## Contribution of the myeloperoxidase-dependent oxidative system to host defence against *Cryptococcus neoformans*

Yasuaki Aratani,<sup>1</sup> Fumiaki Kura,<sup>2</sup> Haruo Watanabe,<sup>2</sup> Hisayoshi Akagawa,<sup>3</sup> Yukie Takano,<sup>3</sup> Akiko Ishida-Okawara,<sup>3</sup> Kazuo Suzuki,<sup>3</sup> Nobuyo Maeda<sup>4</sup> and Hideki Koyama<sup>1</sup>

Correspondence  
Yasuaki Aratani  
yaratani@yokohama-cu.ac.jp

<sup>1</sup>Kihara Institute for Biological Research, Yokohama City University, Maioka-cho 641-12, Totsuka, Yokohama 244-0813, Japan

<sup>2,3</sup>Bacteriology<sup>2</sup> and Bioactive Molecules<sup>3</sup>, National Institute of Infectious Diseases, Toyama 1-23-1, Shinjuku, Tokyo 162-8640, Japan

<sup>4</sup>Department of Pathology and Laboratory Medicine, the University of North Carolina, Chapel Hill, North Carolina 27599-7525, USA

The *in vivo* contribution of reactive oxygen species produced by neutrophils against *Cryptococcus* infection is not widely recognized. Myeloperoxidase (MPO) is a neutrophil-specific enzyme that catalyses the production of hypohalous acids such as HOCl from H<sub>2</sub>O<sub>2</sub>. This study investigated the role of MPO in immunological defence against *Cryptococcus neoformans* in an MPO-deficient (MPO<sup>-/-</sup>) mouse model. The survival of MPO<sup>-/-</sup> mice infected either intranasally or intravenously with *C. neoformans* was lower than that of identically challenged wild-type mice. The MPO<sup>-/-</sup> mice that received intranasal injection of *C. neoformans* had significantly larger lung fungal burdens than wild-type mice. On day 7, MPO<sup>-/-</sup> mice had a significantly higher lung concentration of interleukin (IL)-4 and lower concentrations of IL-2, IL-12p70 and interferon (IFN)- $\gamma$  than wild-type mice, suggesting a weak Th1 response in the MPO<sup>-/-</sup> mice to *C. neoformans*. Pathologically, the MPO<sup>-/-</sup> mice with intranasal infection showed more severe pneumonia than wild-type mice, which was associated with an increase in the levels of IL-1 $\alpha/\beta$  in the lungs. In addition, in MPO<sup>-/-</sup> mice, the pulmonary infection disseminated to the brain with occasional meningitis. The keratinocyte-derived cytokine (KC) level in the brain of infected MPO<sup>-/-</sup> mice was higher than that of control mice. Both intranasal and intravenous infections resulted in a higher number of fungi in the spleen of MPO<sup>-/-</sup> mice compared to wild-type, suggesting decreased resistance to *C. neoformans* not only in the lungs but also in the spleen in the absence of MPO. Taken together, these data suggest a major role of MPO in the response to cryptococcal infection.

Received 10 March 2006

Accepted 26 May 2006

### INTRODUCTION

*Cryptococcus neoformans* is an encapsulated fungus that causes life-threatening infections, particularly in patients with impaired cell-mediated immunity (Chuck & Sande, 1989). The lung is the initial site of *C. neoformans* infection and elicits an influx of macrophages, lymphocytes and neutrophils. Although the infection is typically restricted to the lung, *C. neoformans* disseminates to the central nervous system in the immunosuppressed patient and occasionally in the normal host (Murphy, 1996), and leads to a potentially life-threatening meningoencephalitis (Kozel, 1993). Successful eradication of *C. neoformans* is largely mediated by T cells (Buchanan & Doyle, 2000), and is

dependent on protective Th1 cell-derived cytokines (Kawakami *et al.*, 1996; Yuan *et al.*, 1997).

In addition to cell-mediated immunity, neutrophils have been implicated in protection against *C. neoformans* (Graybill *et al.*, 1997; Miller & Mitchell, 1991; Retini *et al.*, 1996; Vecchiarelli *et al.*, 1998). Whereas normal human neutrophils kill *C. neoformans*, those isolated from patients with chronic granulomatous disease lack fungicidal activity (Diamond *et al.*, 1980). Since chronic granulomatous disease is associated with a defect in the phagocyte NADPH oxidase, this suggests that normal neutrophil anti-cryptococcal activity depends on an intact NADPH oxidase. However, the contribution of neutrophil-derived reactive oxygen species (ROS) to host defence against *C. neoformans* has not been fully characterized.

Abbreviations: H&E, haematoxylin and eosin; IFN, interferon; IL, interleukin; KC, keratinocyte-derived cytokine; MPO, myeloperoxidase.

Myeloperoxidase (MPO) (Hansson *et al.*, 2006; Klebanoff, 2005) is found mainly in neutrophils and to a lesser degree in monocytes. In the presence of hydrogen peroxide ( $H_2O_2$ ), MPO oxidizes chloride to produce the potent microbicidal agent hypochlorous acid. MPO also catalyses the oxidation of bromide, iodide and the pseudohalide ion thiocyanate. MPO deficiency (Lehrer & Cline, 1969; Nauseef, 1998) is the most common inherited neutrophil defect, with an estimated incidence of 1 in 2000–4000 in Europe and the USA (Parry *et al.*, 1981), and of 1 in 55 000 in Japan (Nunoi *et al.*, 2003). Phagocytes deficient in MPO express a mild to moderate defect in bacterial killing but a marked defect in fungicidal activity *in vitro* (Diamond *et al.*, 1980; Parry *et al.*, 1981). Using MPO-deficient ( $MPO^{-/-}$ ) mice, we have previously demonstrated that the MPO-dependent oxidative system is important for *in vivo* host defence against a variety of micro-organisms (Aratani *et al.*, 1999, 2000, 2002a, b). The aim of the present study was to define the contribution of the MPO-dependent antimicrobial system to the *in vivo* host defence against *C. neoformans*.

## METHODS

**Animals.** Animal experimentation was carried out in accordance with the guidelines of Kihara Institute for Biological Research, Yokohama City University. All mice used were 10- to 12-week-old females. C57BL/6 mice were purchased from Japan SLC (Hamamatsu). Homozygous mutant mice for MPO (Aratani *et al.*, 1999) were backcrossed more than ten times with C57BL/6 to ensure similar genetic backgrounds. Before infection, all animals were housed under specific-pathogen-free conditions.

**Experimental infection with *C. neoformans*.** *C. neoformans* (ATCC 24067) was cultured on agar slants containing 2.1% YM broth for 4 days at 27°C. Fungi were enumerated with a haemocytometer, and the viable number determined in c.f.u. For pulmonary infection, wild-type C57BL/6 and  $MPO^{-/-}$  mice were intranasally challenged with 0.04 ml fungal suspension. Thirty minutes later, the lungs of two wild-type and two  $MPO^{-/-}$  mice were removed aseptically and homogenized in 1 ml sterile saline to determine the initial number of organisms. At various time points after the challenge, selected organs (lungs, brain, spleen) were harvested aseptically and homogenized in sterile saline in the presence of protease inhibitors (Complete Protease Inhibitor Cocktail Tablets; Roche). Appropriate dilutions of the homogenates were plated in duplicate onto trypticase soy agar plates (Eiken Chemical). After 2 days incubation at 37°C, the number of viable organisms was determined in c.f.u. Data were recorded as the mean log(c.f.u.) per organ. The remaining homogenates of the lungs and brain were centrifuged at 19 000 g for 10 min to remove cell debris and filtered with 0.45 µm pore-size filters (MILLEX-HV; Millipore). The final supernatants were frozen at -20°C until assayed for cytokines. For intravenous infection, mice were warmed under a heat lamp to vasodilate the tail vein, and fungi were injected in a 0.1 ml volume through a 27-gauge needle. The spleen was removed and homogenized in 1 ml sterile saline and the aliquots were diluted and plated onto the agar plates.

**Quantification of cytokine and chemokine levels.** The lung and brain supernatants were analysed using the Bio-Plex system and a Luminex 100TM analyser (Bio-Rad) according to the manufacturer's instructions. Results were expressed as the mean ± SD. The detection limit of the assay was 1.95 pg ml<sup>-1</sup> for all cytokines and chemokines, as stated by the manufacturer.

**Preparation of sections and slides.** Five wild-type and five  $MPO^{-/-}$  mice were sacrificed for histopathologic examination at the same time points as those for c.f.u. measurement. The whole lungs and brain were removed and fixed in a buffered 4% paraformaldehyde solution, dehydrated in ethanol, and embedded in paraffin for sectioning. The sections of these organs were processed for haematoxylin and eosin (H&E) and Grocott staining using standard protocols. Five well-separated cross sections of each organ were obtained and all available fields were observed by light microscopy.

**Statistical analysis.** Survival curves were analysed by the Kaplan–Meier log-rank test. Differences in the number of c.f.u. were examined by the Mann–Whitney *U* test.  $P < 0.05$  was considered significant.

## RESULTS AND DISCUSSION

To examine the contribution of MPO to immunological defence against pulmonary infection with *C. neoformans*, wild-type and  $MPO^{-/-}$  mice were infected intranasally or intravenously with  $3.6 \times 10^6$  or  $8.7 \times 10^5$  viable yeast, respectively. After 6 months intranasal infection, there was a 94% survival rate among infected wild-type mice (Fig. 1a), and all of the intravenously infected wild-type mice remained viable after 3 months (Fig. 1b). Thus, the dose of *C. neoformans* induced minimal mortality in C57BL/6 control mice. In contrast, there was rapid death in  $MPO^{-/-}$  mice infected with *C. neoformans*, with a 100% death rate before 1 month and 4 months of intravenous and intranasal infection, respectively (Fig. 1a, b). The difference in survival rates between wild-type and  $MPO^{-/-}$  mice was highly significant ( $P < 0.001$ ).

We reasoned that the most likely explanation for the increased mortality in  $MPO^{-/-}$  mice following intranasal inoculation of *C. neoformans* was an impaired clearance of the initial inoculum from the airway. To assess this possibility, we compared the lung fungal burden in  $MPO^{-/-}$  mice to that of wild-type controls (Fig. 2). Nearly half of the inoculum,  $1.7 \times 10^6$  fungi, was recovered from the lung of wild-type and  $MPO^{-/-}$  mice 30 min after infection. The number of *C. neoformans* in the lungs increased simultaneously for the first 7 days in both groups and peaked on day 19, with a slightly but significantly higher number of c.f.u. in the  $MPO^{-/-}$  mice. In the wild-type mice, a gradual elimination of the fungi occurred between days 19 and 34, but the  $MPO^{-/-}$  mice failed to eliminate *C. neoformans* from the lung. Consequently, by day 60,  $MPO^{-/-}$  mice contained nearly 200-fold more fungi than the infected control group ( $P < 0.01$ ).

Minimal inflammation was observed histopathologically on day 7, irrespective of genotype, and similar degrees of inflammation were observed on day 19 in both groups (Fig. 3). The lungs of infected wild-type mice showed only localized areas of leukocyte infiltration at days 34 and 60, whereas  $MPO^{-/-}$  mice at day 34 exhibited extensive areas of inflammatory infiltration, and all of the airway spaces were filled with the inflammatory cells at day 60. Thus, the lung c.f.u. and the development of pulmonary inflammation correlated with the increased mortality in  $MPO^{-/-}$  mice.